-
TMB Substrate Solution: Evidence and Scope
2026-10-16
APExBIO identifies K1131 as a TMB substrate solution for ELISA, but the available product information does not document composition, reaction conditions, performance data, or an identity-matched research study. Its scientifically supportable interpretation is therefore limited to a product-level role in chromogenic assay readout, not a validated performance claim.
-
FPH1 (BRD-6125): Evidence and Scope
2026-10-15
FPH1, also known as BRD-6125, is described by APExBIO as a small molecule associated with increased hepatocyte proliferation and functional readouts in primary human hepatocytes and iPSC-derived hepatocyte-like cells. The available product information supports a phenotype-level interpretation involving cell number, mitotic activity, albumin, CYP3A4, and AFP, but it does not establish a molecular target, causal pathway, quantitative effect size, or independent study validation.
-
Alvimopan Dihydrate: Evidence and Scope
2026-10-15
The APExBIO listing identifies Alvimopan dihydrate as catalog SKU A3163, but the available product information provides no mechanism statement, assay context, or identity-matched research paper. The defensible interpretation is therefore limited to catalog identity; pharmacological mechanism, measurement meaning, efficacy, and comparative performance cannot be established from this record.
-
DiscoveryProbe™ Library: Evidence and Scope
2026-10-14
APExBIO describes the DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) as a 2,320-compound collection of clinically approved or pharmacopeia-listed bioactive molecules supplied in DMSO for screening-oriented research. Its principal scientific value is breadth of pharmacological perturbation, not a single shared mechanism. The available evidence documents product identity, formulation, and intended applications, but provides no identity-matched study establishing assay performance, target engagement, phenotype size, reproducibility, or therapeutic relevance.
-
Rilpivirine: Identity and Evidence Scope
2026-10-14
Rilpivirine, also known as TMC278, is identified in the APExBIO catalog as a second-generation non-nucleoside reverse transcriptase inhibitor associated with HIV-1 research. Because no matched paper is available, the available evidence supports only catalog-level identity and conceptual research scope—not independent conclusions about efficacy, resistance coverage, clinical outcomes, or experimental performance.
-
Lysoptosis, Serpins and What BV6 Does Not Show
2026-10-13
The cited study proposes lysoptosis as a conserved lysosome-dependent cell-death pathway regulated by intracellular serpins. Its findings provide a mechanistic framework distinct from the IAP-antagonist activity described for BV6, but they do not establish that BV6 induces lysoptosis or support therapeutic conclusions.
-
Dexamethasone Evidence Gaps in Myeloma Models
2026-10-13
The 2019 Theranostics study provides a valuable genomic map of 30 human multiple myeloma cell lines and reports associations between mutations and responses to ten drugs. However, it does not establish that dexamethasone-specific responses are transferable across models, nor does it connect supplier-described mechanisms such as inhibition of NF-κB signaling, mesenchymal stem cell differentiation, or autophagy induction in lymphoblastic cells to multiple myeloma biology.
-
Realgar, L-Ornithine, and the Liver–Brain Axis
2026-10-12
A 2025 Advanced Science study proposes that realgar-derived arsenic may connect hepatic OTC disruption and ornithine accumulation with ZBTB7A-mediated suppression of astrocyte glycolysis. The evidence is mechanistically integrated but remains preclinical, model-dependent, and insufficient to establish human causation or clinical treatment implications.
-
Targeted BRD7 Demethylation in Nasopharyngeal Carcinoma
2026-10-12
This study examined whether targeted removal of methylation from the BRD7 promoter could restore BRD7 expression and restrain nasopharyngeal carcinoma progression. The reported results support a model in which BRD7 promoter hypermethylation contributes to gene silencing and malignant phenotypes in the tested models, but they do not establish clinical efficacy, genome-wide specificity, or equivalence to Decitabine.
-
Morin, AMPD2, and Podocyte Energy Failure
2026-10-10
A 2025 study links fructose-associated podocyte injury to altered purine nucleotide cycling, mitochondrial dysfunction, and compensatory glycolysis, identifying AMPD2 as a mechanistic candidate. Its findings suggest that Morin can moderate this phenotype in cell and rat models, while leaving important questions about direct target engagement, pharmacology, and human relevance unresolved.
-
How ICAA Disrupts HBV Through HO-1 and ROS
2026-10-10
A 2026 Antiviral Research study links isochlorogenic acid A with suppression of several hepatitis B virus life-cycle stages, including transcription, cccDNA-associated replication, capsid formation, and envelopment. Its central contribution is a mechanistic model connecting these effects with HO-1 upregulation, altered intracellular ROS, and possible disruption of thiol-dependent viral protein maturation.
-
Anti-b, mTOR Signaling, and Hepatic Steatosis
2026-10-09
The reference study presents Anti-b as a low-molecular-weight compound that reduced diet- or oleic acid-associated dyslipidaemia and hepatic lipid accumulation in preclinical models. Its central innovation is the proposed connection between mTOR regulation and downstream PPARγ and SREBP1 lipid-metabolism pathways, although the findings remain preclinical and require independent validation.
-
L-Leucine and the Future of Stable mRNA-LNPs
2026-10-09
Drying may help move mRNA-LNPs beyond ultra-cold storage, but the central translational challenge is preserving both RNA integrity and nanoparticle function. This thought-leadership analysis positions L-Leucine as a hypothesis-generating research variable—not a proven stabilizer—and outlines how researchers can evaluate its relevance without confusing biological rationale with formulation evidence.
-
SAG and Evidence-Centered Hedgehog Model Design
2026-10-08
SAG is more than a Hedgehog pathway activator: it is a pharmacological reference for separating Smoothened-level effects from downstream phenotypes. This evidence-centered guide explains how to interpret SAG across pathway assays, neural models, developmental research, and tumorigenesis studies.
-
Pifithrin-α and p53 in Neurotoxicity Research
2026-10-08
Pifithrin-α is a small-molecule p53 inhibitor used as a hypothesis-testing tool in apoptosis, cell-cycle, and ferroptosis research. A 2025 rat and cell study associated maternal deltamethrin exposure with impaired memory, hippocampal injury, and p53-linked ferroptosis in male offspring. The evidence supports a mechanistic research model, but does not establish that Pifithrin-α is a selective treatment, environmental antidote, or clinically validated strategy for reducing cancer-therapy toxicity.